A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.

@article{Pillot2006API,
  title={A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.},
  author={Giancarlo A Pillot and William J. L. Read and Kristin L Hennenfent and Sharon Marsh and Feng Gao and Avinash K Viswanathan and Kristopher W. Cummings and Ping Liao and Ramaswamy Govindan},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2006},
  volume={1 9},
  pages={972-8}
}
PURPOSE We conducted a phase II study of carboplatin and irinotecan in patients with advanced non-small cell lung cancer (NSCLC). In addition, we studied the correlation between certain genotypes of enzymes involved in irinotecan metabolism with efficacy and toxicity. PATIENTS AND METHODS Patients with stage IIIB, IV, or recurrent NSCLC received a combination of irinotecan and carboplatin every 3 weeks at a dose of 200 mg/m2 and area under the curve of 5. Pharmacogenomic analysis was… CONTINUE READING
14 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…